Cargando…

Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple‐negative breast cancer

BACKGROUND: Although neoadjuvant chemotherapy (NAC) is currently the best therapy for triple‐negative breast cancer (TNBC), resistance still occurs in a considerable proportion, thus it is crucial to understand resistance mechanisms and identify predictive biomarkers for patients selection. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yanhui, Zhang, Hongfei, Pan, Chaohu, He, Gao, Cui, Xiaoli, Yu, Xiafei, Zhang, Xiaoqiang, Wu, Dongfang, Yang, Junzhe, Wu, Xian, Luo, Haitao, Liu, Xiaoan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028167/ https://www.ncbi.nlm.nih.gov/pubmed/36271505 http://dx.doi.org/10.1002/cam4.5372

Ejemplares similares

Deubiquitinase USP19 modulates apoptotic calcium release and endoplasmic reticulum stress by deubiquitinating BAG6 in triple negative breast cancer
por: Zhang, Xiaoqiang, et al.
Publicado: (2023)

Comprehensive analysis of pyroptotic gene prognostic signatures associated with tumor immune microenvironment and genomic mutation in breast cancer
por: Zhang, Hongfei, et al.
Publicado: (2022)

Comprehensive Analysis of the Immune-Oncology Targets and Immune Infiltrates of N(6)-Methyladenosine-Related Long Noncoding RNA Regulators in Breast Cancer
por: Zhang, Xiaoqiang, et al.
Publicado: (2021)

Comprehensive evaluation of cell death-related genes as novel diagnostic biomarkers for breast cancer
por: Shi, Xiaoyue, et al.
Publicado: (2023)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

LHX2 Is a Potential Biomarker and Associated with Immune Infiltration in Breast Cancer
por: Zhang, Ziwei, et al.
Publicado: (2023)

Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial
por: Zhang, Guoqing, et al.
Publicado: (2023)

Crosstalk of RNA methylation writers defines tumor microenvironment and alisertib resistance in breast cancer
por: Zhang, Xiaoqiang, et al.
Publicado: (2023)

Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
por: Sarradin, Victor, et al.
Publicado: (2021)

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
por: Wang, Gang, et al.
Publicado: (2023)

Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature
por: Qin, Yan, et al.
Publicado: (2021)

The Identification of Two RNA Modification Patterns and Tumor Microenvironment Infiltration Characterization of Lung Adenocarcinoma
por: He, Wan, et al.
Publicado: (2022)

Corrigendum: The Identification of Two RNA Modification Patterns and Tumor Microenvironment Infiltration Characterization of Lung Adenocarcinoma
por: He, Wan, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making
por: Sun, Daqiang, et al.
Publicado: (2022)

Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Lin, Yuxiang, et al.
Publicado: (2022)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation
por: Zheng, Hongmei, et al.
Publicado: (2021)

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
por: Amos, Keith D., et al.
Publicado: (2012)

Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
por: Fitzpatrick, Amanda, et al.
Publicado: (2019)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer
por: Ye, Jia-hui, et al.
Publicado: (2021)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
por: Fan, Yiqi, et al.
Publicado: (2022)

Crosstalk between triple negative breast cancer and microenvironment
por: Smrekar, Karly, et al.
Publicado: (2023)

Integrating Genomic Information with Tumor-Immune Microenvironment in Triple-Negative Breast Cancer
por: Otohinoyi, David, et al.
Publicado: (2022)

Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
por: Lejeune, Marylène, et al.
Publicado: (2023)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer
por: Xiao, Yan, et al.
Publicado: (2022)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
por: Silva, Diogo, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures
por: Ji, Fei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c3mkfr6b9v9ntu41uj6fbfv70d